---
title: Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
date: '2024-06-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38832972/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240604181902&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy
  in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were
  ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support
  Grant; IMROZ ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, ...